<DOC>
	<DOCNO>NCT00775606</DOCNO>
	<brief_summary>The ideal anti-HIV medication patient advance HIV disease unknown . There evidence anti-HIV regimen contain protease inhibitor enhance immune function well regimen contain protease inhibitor . This study determine difference immune enhancement capability anti-HIV regimen contain protease inhibitor - lopinavir-ritonavir , regimen contain efavirenz . Both medication recommend first line treatment HIV-infected patient . This study recruit HIV-positive patient need start anti-HIV treatment CD4+ T-cells 200 . The usual threshold start treatment CD4+ T-cell less 350 . Subjects randomize treatment either anti-HIV regimen contain lopinavir-ritonavir regimen contain efavirenz . The study determine difference immune reconstitution 24 week treatment study medication . Among immune parameter measure ability subject respond vaccination tetanus-diphtheria vaccine 23-valent pneumococcal vaccine . Both vaccine also recommend HIV-positive patient HIV-positive patient tend low response rate vaccine .</brief_summary>
	<brief_title>Immune Reconstitution Lopinavir/Ritonavir-Based v Efavirenz-based HAART Advanced HIV Disease</brief_title>
	<detailed_description>DESIGN : ICE-001 phase IV , randomize , two-arm unblinded study , compare effect immune reconstitution open-label ritonavir ( RTV ) -enhanced lopinavir ( LPV ) efavirenz ( EFV ) , combination daily emtricitabine ( FTC ) /tenofovir ( TDF ) initial therapy HIV-1 infection HIV-infected treatment naïve subject CD4+ T-cells le 200 cells/ml . DURATION : Subjects participate ICE-001 approximately 48 week start study treatment . SAMPLE SIZE : ICE-001 enroll 60 subject ( 30 per treatment arm ) . POPULATION : HIV-1-infected , antiretroviral ( ARV ) drug-naïve ( ≤7 day ARV treatment anytime prior study entry ) men woman between18 60 year age plasma HIV-1 RNA level &gt; 1000 copies/mL CD4+ T-cell count &lt; 200 cells/ml obtain within 90 day prior study entry . STRATIFICATION : Subjects stratify screen base plasma HIV-1 RNA level &lt; 100,000 ≥100,000 copies/mL . REGIMEN : At entry subject randomize one following : - ARM A : LPV 400 mg/RTV 100 mg BID + FTC 200 mg/TDF 300 mg QD - ARM B : EFV 600 mg QD/FTC 200 mg/TDF 300 mg fix dose combination QD The objective determine difference degree immune reconstitution HIV-infected patient CD4+ T-cell count &lt; 200 cells/ml initiate treatment LPV/RTV + FTC/TDF compare EFV/FTC/TDF . Study visit occur screen , pre-entry , entry week 1 , 4 , 8 , 12 , 24 48 study entry . Study medication provide entry randomization . At study visit , clinical assessment , include history , physical exam determination drug adherence , occur . Blood hematologic metabolic safety assessment assessment immune parameter obtain . Immune parameter measure include level T-cell apoptosis , maturation activation . Frequencies various T-cell subset lymphocyte population also do . Response vaccination tetanus-diphtheria vaccine 23-valent pneumococcal polysaccharide vaccine ( give week 8 ) measure .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>1 . HIV1 infection 2 . The absence exclusionary resistance mutation genotypic resistance assay 3 . Antiretroviral ( ARV ) drugnaïve 4 . Screening HIV1 RNA &gt; 1000 copies/mL 5 . Screening CD4+ Tcell count &lt; 200 cells/ml 6 . Laboratory value obtain within 30 day prior study entry . Absolute neutrophil count ( ANC ) &gt; 500/mm3 Hemoglobin &gt; 8.0 g/dL Platelet count &gt; 40,000/mm3 AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &lt; 5 x ULN Total bilirubin &lt; 2.5 x ULN Calculated creatinine clearance ≥60 mL/min ( CockcroftGault equation ) 7 . For woman reproductive potential , negative serum urine pregnancy test within 48 hour prior initiate study medication . 8 . Contraception requirement 9 . Men woman age &gt; 18 year &lt; 60 year . 10 . Ability willingness subject legal guardian/representative give write informed consent . 1 . Currently breastfeed . 2 . Use immunomodulators , vaccine , growth hormone , systemic cytotoxic chemotherapy , investigational therapy within 30 day prior study entry . 3 . Known allergy/sensitivity study drug , pneumococcal polysaccharide vaccine , tetanusdiphtheria vaccine 4 . Receipt pneumococcal polysaccharide vaccine tetanusdiphtheria vaccine past 5 year . 5 . Active drug alcohol use dependence 6 . Serious illness require systemic treatment and/or hospitalization candidate either completes therapy clinically stable therapy , opinion site investigator , least 14 day prior study entry . 7 . Requirement current medication prohibit study treatment . 8 . Evidence major resistanceassociated mutation genotype evidence significant resistance phenotype perform time prior study entry 9 . Current anticipated imprisonment involuntary incarceration medical facility psychiatric physical ( e.g. , infectious disease ) illness 10 . History , current bipolar disorder , major depression , schizophrenia psychotic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>AIDS , HIV</keyword>
</DOC>